Evidence map›Paper›PMID 39640287›Full record

ArticleGynecologic oncology reports2024

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy.

Brittany File, Anjali Hari, Ling Bei

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brittany FileDepartment of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA, USA.
Anjali HariDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA.
Ling BeiDepartment of Ophthalmology, Long Beach Memorial Medical Center, Long Beach, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

•Mirvetuximab soravtansine (MIRV) is used in the treatment of FRα positive, platinum-resistant epithelial ovarian cancer.•MIRV is associated with ocular events, leading to dose delays, dose reductions, and discontinuations of chemotherapy.•Mitigation strategies to prevent treatment disruption have historically relied on corticosteroid and lubricating drops.•Dehydrated amniotic membrane patch to treat MIRV related ocular events is a novel therapeutic option.

Indexed as

Amniotic membrane patchCase reportElahere therapyMirvetuximab soravtansine (MIRV)Ocular event

Identifiers

PMID39640287
PMCPMC11617700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.